GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omeros Corp (NAS:OMER) » Definitions » Ending Cash Position

Omeros (Omeros) Ending Cash Position : $1.83 Mil (As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Omeros Ending Cash Position?

Omeros's Ending Cash Position for the quarter that ended in Mar. 2024 was $1.83 Mil.

Omeros's quarterly Ending Cash Position declined from Sep. 2023 ($30.64 Mil) to Dec. 2023 ($7.11 Mil) and declined from Dec. 2023 ($7.11 Mil) to Mar. 2024 ($1.83 Mil).

Omeros's annual Ending Cash Position declined from Dec. 2021 ($100.81 Mil) to Dec. 2022 ($11.01 Mil) and declined from Dec. 2022 ($11.01 Mil) to Dec. 2023 ($7.11 Mil).

Omeros Ending Cash Position Historical Data

The historical data trend for Omeros's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omeros Ending Cash Position Chart

Omeros Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.08 10.50 100.81 11.01 7.11

Omeros Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.83 6.60 30.64 7.11 1.83

Omeros Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Omeros's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=11.009+-3.904
=7.11

Omeros's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=7.105+-5.274
=1.83

Omeros Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Omeros's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Omeros (Omeros) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omeros Corp (NAS:OMER) » Definitions » Ending Cash Position
Comparable Companies
VSTM ALDX PBYI CRMD INMB GOSS SYRS DRTS XOMA ZURA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XKRX:068270 BNTX ALNY
Traded in Other Exchanges
3O8:Germany
Address
201 Elliott Avenue West, Seattle, WA, USA, 98119
Website
https://www.omeros.com
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
Executives
Demopulos Gregory A Md director, 10 percent owner, officer: Chairman, CEO & President 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Demopulos Peter A Md director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Arnold C Hanish director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Thomas J. Cable director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Diana T. Perkinson director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Michael A Jacobsen officer: VP Finance and CAO 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Kurt Zumwalt director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Peter B Cancelmo officer: See Remarks 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Thomas F. Bumol director 201 ELLIOT AVENUE WEST, SEATTLE WA 98119
Marcia S. Kelbon officer: VP Patent and General Counsel 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Ray Aspiri director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Hood Leroy E. Md Phd director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Rajiv Shah director C/O ARCADIA BIOSCIENCES, INC., 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Jean-philippe Tripet director 1420 FIFTH AVENUE, SUITE 2600, SEATTLE WA 98101-2347